AC Immune's PET tracer to be presented at AAIC

By staff writers

July 24, 2020 -- A researcher from Swiss biopharmaceutical company AC Immune will present findings on the company's alpha-synuclein-PET tracer program at the virtual 2020 Alzheimer's Association International Conference (AAIC).

During a 28 June presentation, AC Immune research scientist Francesca Capotosti, PhD, will discuss the development of a PET tracer for the diagnosis of a‑synucleinopathies, which can help in the diagnosis of Parkinson's disease. The presentation will take place during a panel covering non-Alzheimer's neurodegenerative disorders at the conference.

The company will also have research on a phase IB clinical trial of its anti-Abeta vaccine ACI-24 presented at AAIC. The trial is the first large, multinational study on clinical and biomarker changes of Down-syndrome-related Alzheimer's disease, according to AC Immune.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking